When does the accumulated clinical data—i.e. cavitation, symptom severity, etc.—support the use for amikacin, either systemically or with the inhaled liposome suspension, for MAC lung disease?

When does the accumulated clinical data—i.e. cavitation, symptom severity, etc.—support the use for amikacin, either systemically or with the inhaled liposome suspension, for MAC lung disease?

CLICK HERE FOR CME CREDIT

When does the accumulated clinical data—i.e. cavitation, symptom severity, etc.—support the use for amikacin, either systemically or with the inhaled liposome suspension, for MAC lung disease?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | NTM-Pulmonary Infection Intelligence Zone

Presenter

Antonio Catanzaro, MD

Antonio Catanzaro, MD

Professor of Medicine
Previously, Director, Tuberculosis Control
Division of Pulmonary, Critical Care, and Sleep Medicine
UC San Diego School of Medicine
San Diego, California